STING1 and breast carcinoma: This has prompted significant recent clinical evaluation of STING agonists based on extensive preclinical validation of therapeutic efficacy in multiple murine models of cancer, including pancreatic cancer (27), melanoma (28, 29), mammary carcinomas (28, 30), and colorectal carcinoma (31), among a growing list of other solid tumors.